Copyright © 2010, Research To Practice, All rights reserved. Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer Andrew Tutt, MB ChB, PhD.

Slides:



Advertisements
Similar presentations
Triple negative breast cancer
Advertisements

A trial for women with –‘Triple negative’ breast cancer (TNBC) –Localised to breast +/- lymph nodes –Recommended standard treatment involves NEPTUNE Taxane.
Robertson JFR et al. J Clin Oncol 2009;27(27):
Can We Define Tumors That Will Respond to PARP Inhibitors? A Phase II Correlative Study of Olaparib in Advanced Serous Ovarian Cancer and Triple-Negative.
Targeted Therapy: A Giant Step Forward
Princess Margaret Hospital, Co-Chair Gynecology, NCIC CTG
PARP Inhibition: A New Approach To Cancer Therapy? Dr. Geert Kolvenbag
Unanswered Questions in Primary Treatment of Ovarian Cancer: Controversial Areas Deborah K. Armstrong, M.D. May 29, 2009.
Understanding and Treating Triple-Negative Breast Cancer Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center Wichita,
Successful treatment of pediatric desmoid tumors using hydroxyurea Naomi Balamuth, M.D. Richard Womer, M.D. November 13, 2008.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation 1 Phase III Randomized, Open-Label, Multicenter Trial (BRIM3) Comparing BRAF Inhibitor.
PARP Inhibitors: Usurping DNA repair to target cancer
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
Panagiotis Konstantinopoulos MD, PhD Assistant Professor of Medicine
The Role of PARP inhibitors in Breast Cancer QROC November 5 th, 2010 Rebecca Dent, MD FRCP(C) Sunnybrook Odette Cancer Center Toronto, Canada.
Phase 1b Study of Iniparib (BSI-201) Combined with Irinotecan for Treatment of Metastatic Breast Cancer 1 Cell Cycle Effects of Iniparib plus Gemcitabine.
BRCA2 Clark Cunningham March 26, 2015 BIOL445 American Cancer Society, eastcancer/make-a-pink-ribbon-lapel-pin,
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer Trial Study Regimen No. of Patients Disease-Free Survival (%) Hazard Ratio P-Value Overall.
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin in Triple Negative Metastatic Breast Cancer: Results of a Phase II Study.
Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.
Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)
Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results.
O’Shaughnessy J et al. Proc ASCO 2011;Abstract 1007.
Xeloda ® monotherapy in pancreatic cancer: phase II study  42 patients with advanced/metastatic pancreatic cancer received intermittent Xeloda 1,250mg/m.
Activity and Tolerability of Afatinib (BIBW 2992) and Cetuximab in NSCLC Patients with Acquired Resistance to Erlotinib or Gefitinib Janjigian YY et al.
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
Results of a Randomized Phase 2 Study of PD , a Cyclin ‐ Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone.
Audeh MW et al. ASCO 2009; Abstract (Clinical Science Symposium)
A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.
12 th Annual CTOS Meeting 2006 AP23573 Induced Long-term Stability in 2 Patients with Desmoplastic Small Round Cell Tumor (#561) Scott Schuetze, Warren.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Mok TS, Wu SL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: Gefitinib Superior.
A Phase I Study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer May Cho, Dean Lim, Timothy Synold, Paul Frankel, Lucille Leong,
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer In association.
May 29 - June 2, 2015 TIGER-X: Rociletinib Activity in EGFR T790M Mutant NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* *CCO.
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
Research Update on PARP Inhibition: Emerging Data in Breast, Ovarian, and Other Cancers William J. Gradishar, MD, FACP Professor of Medicine Director.
SK Sandhu 1,2, R Wenham 3, G Wilding 4, M McFadden 5, L Sun 5, C Toniatti 5, M Stroh 5, C Carpenter 5, J de-Bono 1,2, WR Schelman 4 First in Human Trial.
Department of Surgical, Oncological and Oral Sciences U.O.C Medical Oncology Director: Prof A. Russo Ovarian cancer Case Report 1 Dr. Lorena Incorvaia,
May 29 - June 2, 2015 KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1- Positive Extensive-Stage SCLC CCO Independent Conference.
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
The Long and Winding Road of PARP Inhibitors in Breast Cancer
Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
CCO Independent Conference Coverage
CCO Independent Conference Highlights
Gajria D et al. Proc SABCS 2010;Abstract P
Vahdat L et al. Proc SABCS 2012;Abstract P
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination With Chemotherapy in Early-Stage TNBC CCO Independent Conference Highlights*
Targeting the DNA Damage Response in Cancer
An Introduction to DNA Damage Repair in Cancer: Beyond PARP
Fowler NH et al. Proc ASCO 2010;Abstract 8036.
PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
Krop I et al. SABCS 2009;Abstract 5090.
Figure 1 Putative anticancer mechanisms of action of PARP inhibitors
Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian cancer Dr Giorgio Valabrega University of Torino,
Volume 137, Issue 2, Pages (May 2015)
- Phase 1 Signalling Study
Phase II trial of erlotinib in advanced pancreatic cancer
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma1 Phase 3 Randomized Study of Ipilimumab (IPI) plus Dacarbazine (DTIC) vs DTIC.
R Hermann6, P Sportelli7, L Gardner7 and J Bendell8
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Presentation transcript:

Copyright © 2010, Research To Practice, All rights reserved. Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer Andrew Tutt, MB ChB, PhD Consultant Oncologist/Director Breakthrough Breast Cancer Research Unit King’s Health Partners Academic Health Science Centre London, United Kingdom

Copyright © 2010, Research To Practice, All rights reserved. Advisory Committee AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis HonorariaAstraZeneca Pharmaceuticals LP, Sanofi-Aventis Disclosures for Andrew Tutt, MB ChB, PhD

Copyright © 2010, Research To Practice, All rights reserved. DNA repair mechanisms in cells Base-excision repair (PARP) Nucleotide-excision repair Recombinational repair (BRCA1/BRCA2) Mismatch repair

Copyright © 2010, Research To Practice, All rights reserved. Double Strand Break Repair Pathways Copyright © 2010, Research To Practice, All rights reserved. Tutt A et al. Cold Spring Harb Symp Quant Biol 2005;70:139–148

Copyright © 2010, Research To Practice, All rights reserved. How to target loss of BRCA1 or BRCA2 function? Lesions that arrest DNA replication forks Loss of homologous recombination How could we exploit defect ? Platinum cross-links ? Topo-1 inhibitors ? Alkylating agents ? PARP inhibitors ? Tutt A et al. Cold Spring Harb Symp Quant Biol 2005;70:139–148

Copyright © 2010, Research To Practice, All rights reserved. Reprinted with permission from Zander SA et al. Cancer Res 2010;7a0: , figure 3. BRCA1 mutation basal-like breast cancer mouse model

Copyright © 2010, Research To Practice, All rights reserved. Lig3 XRCC1 Polß PNK Tutt A on behalf of ICEBERG investigators. ASCO 2009;Abstract CRA501 Poly (ADP-ribose) polymerase (PARP) A key regulator of DNA damage repair processes Involved in DNA base-excision repair (BER) Binds directly to DNA damage Produces large branched chains of poly (ADP-ribose) Attracts and assists BER repair effectors

Copyright © 2010, Research To Practice, All rights reserved. BRCA1/BRCA2 failure Chromosomal Instability Cell Death Impaired HR repair Alternative error prone repair SSB PARPi  H2AX HR-based repair Normal BRCA1/BRCA2 Chromosome Stability Cell Survival DNA replication fork arrest and collapse RAD51 Farmer H et al. Nature 2005;434:917–921; Bryant HE et al. Nature 2005;434:913–917 PARP inhibition and tumor selective synthetic lethality

Copyright © 2010, Research To Practice, All rights reserved. DNA DAMAGE BRCA1 or BRCA2 Carrier Normal tissue BRCA1 or BRCA2 Carrier Tumor tissue HR NHEJ SSA BER NER etc Tumor-specific lethality xx x Targeting BRCA for tumor selective killing Tutt A et al. Cold Spring Harb Symp Quant Biol 2005;70:139–148; McCabe N et al. Cancer Res 2006;66:8109–8115

Copyright © 2010, Research To Practice, All rights reserved. Olaparib: A novel, orally active PARP inhibitor A phase I trial identified olaparib (AZD2281; KU ) 400 mg bid as the maximum tolerated dose 1 with a 28% (13/46 pts) response rate (RECIST) in BRCA-mutated ovarian cancer 2 Most common toxicities: CTCAE Grade 1 and 2 nausea and fatigue Significant PARP inhibition and tumor response at olaparib doses 100–400 mg bid Copyright 2009 Massachusetts Medical Society. All rights reserved. 1. Yap T et al. J Clin Oncol 2007;25(18S):abst Fong PC et al. N Engl J Med 2009;361(2): Copyright © 2010, Research To Practice, All rights reserved.

Study no: D0810C00008; KU36-44 Phase II Trial of the Oral PARP Inhibitor Olaparib in BRCA-Deficient Advanced Breast Cancer Andrew Tutt 1, Mark Robson 2, Judy E Garber 3, Susan Domchek 4, M William Audeh 5, Jeffrey N Weitzel 6, Michael Friedlander 7, James Carmichael 8 1 Breakthrough Breast Cancer Research Unit, Guy's Hospital, King's Health Partners, London, UK 2 Memorial Sloan-Kettering Cancer Center, New York, NY, USA 3 Dana-Farber Cancer Institute, Boston, MA, USA 4 University of Pennsylvania, Philadelphia, PA, USA 5 Cedars-Sinai Cancer Center, Los Angeles, CA, USA 6 City of Hope Comprehensive Cancer Center, Duarte, CA, USA 7 Prince of Wales Cancer Centre, Randwick, Sydney, New South Wales, Australia 8 AstraZeneca, Macclesfield, UK

Copyright © 2010, Research To Practice, All rights reserved. Confirmed BRCA1 or BRCA2 mutation Advanced refractory breast cancer (stage IIIB/IIIC/IV) after failure of ≥1 prior chemotherapy for advanced disease Olaparib 400 mg po bid (MTD) 28-day cycles; n = 27 Cohort 1 (enrolled first) Tutt A on behalf of ICEBERG investigators. ASCO 2009;Abstract CRA501 To assess the efficacy and tolerability of oral olaparib in BRCA1/ BRCA2 mutation carriers with breast cancer Proof-of-concept phase II study, single-arm sequential cohort design Study design and eligibility Olaparib 100 mg po bid 28-day cycles; n = 27 Cohort 2

Copyright © 2010, Research To Practice, All rights reserved. *An additional 1 patient in the 400 mg cohort and 3 patients in the 100 mg cohort had unconfirmed responses Efficacy ITT cohort Olaparib 400 mg bid (n = 27) Olaparib 100 mg bid (n = 27) Overall Response Rate, n (%)11 (41)*6 (22)* Complete Response, n (%)1 (4)0 Partial Response, n (%)10 (37)6 (22) Copyright © 2010, Research To Practice, All rights reserved. Tutt A on behalf of ICEBERG investigators. ASCO 2009;Abstract CRA501

Copyright © 2010, Research To Practice, All rights reserved. Best % change from baseline – 100 – 80 – 60 – 40 – BRCA 1 BRCA 2 Increasing tumor shrinkage Olaparib 400 mg bid cohort One patient was excluded as only 1 of their 2 target lesions was measured at each assessment Best percent change from baseline in target lesions by genotype Copyright © 2010, Research To Practice, All rights reserved. Tutt A on behalf of ICEBERG investigators. ASCO 2009;Abstract CRA501

Copyright © 2010, Research To Practice, All rights reserved. BRCA1 downregulation High histological grade Medullary histological type Metaplastic histological type Basal-like IHC phenotype With permission from Hanneman J. EBCC ;Abstract 308; Turner et al. Oncogene 2007; Rakha, Reis-Filho, Ellis; J Clin Oncol 2008 Copyright © 2010, Research To Practice, All rights reserved.

2 cm Stage II/III Triple Negative (ER/PR/HER2 Negative) Surgery Phase II Single Arm Trial N = 28 median age: 50 yrs median tumor size = 3.0 cm ( cm) 2 BRCA1 mutation carriers Silver DP et al. J Clin Oncol 2010; 28: pCR – 22% - incl 2 BRCA1 carriers Good MP Score 3-5 – 50% Minor response MP 1-2 – 36% Progression 14% Triple Negative Neoadjuvant Trial Copyright © 2010, Research To Practice, All rights reserved. CISPLATIN 75mg/m 2 q 3wks IV x 12 wks

Copyright © 2010, Research To Practice, All rights reserved. Silver DP et al. J Clin Oncol 2010;28: Reprinted with permission American Society of Clinical Oncology. All rights reserved. Impaired BRCA1 and neoadjuvant cisplatin response in TNBC Copyright © 2010, Research To Practice, All rights reserved.

Essential role for nuclear PTEN in maintaining chromosomal integrity Shen et al Cell 128, 157–170, January 12, 2007 PTEN pathway loss common in TN/basal-like (Saal LH Nat Genet. 2008;40:102–107, Marty Breast Cancer Res. 2008; 10(6), López-Knowles Int J Cancer Aug 14) Loss of PTEN causes a reduction in HR repair and induces sensitivity to PARP inhibition (Mendes-Pereira A, EMBO Mol Med 1(6-7) 2009) PTEN pathway loss and loss of HR repair and PARPi sensitivity

Copyright © 2010, Research To Practice, All rights reserved. Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin in Triple Negative Metastatic Breast Cancer: Results of a Phase II Study Joyce O’Shaughnessy 1,2,4, Cynthia Osborne 1,2,4, John Pippen 1,2,4, Debra Patt 3,4, Christine Rocha 5, Valeria Ossovskaya 5, Barry M. Sherman 5, Charles Bradley 5 1 Baylor Sammons Cancer Center 2 Texas Oncology, Dallas, TX 3 Texas Oncology Cancer Center, Austin, TX 4 US Oncology, Dallas, TX 5 BiPar Sciences, Inc., Brisbane, CA

Copyright © 2010, Research To Practice, All rights reserved. 21-Day Cycle * Patients randomized to gem/carbo alone could crossover to receive gem/carbo + BSI-201 at disease progression BSI-201 (5.6 mg/kg, IV, d 1, 4, 8, 11) Gemcitabine (1,000 mg/m 2, IV, d 1, 8) Carboplatin (AUC 2, IV, d 1, 8) Gemcitabine (1,000 mg/m 2, IV, d 1, 8) Carboplatin (AUC 2, IV, d 1, 8) RESTAGING Every 2 Cycles Metastatic TNBC N = 120 O’Shaughnessy et al. ASCO 2009 RANDOMIZE Gem/Carbo +/- BSI-201 in unselected TNBC

Copyright © 2010, Research To Practice, All rights reserved. Gem/Carbo (n = 44) BSI Gem/Carbo (n = 42) p-value Objective Response Rate n (%)7 (16%)20 (48%)0.002 **Clinical Benefit Rate n (%)9 (21%)26 (62%) *Includes patients enrolled before September 30, 2008 and patients who had a confirmed response or disease progression **Clinical Benefit Rate = CR + PR + SD ≥ 6 months Preliminary Efficacy Results* Copyright © 2010, Research To Practice, All rights reserved.

With permission from O’Shaughnessy et al. SABCS 2009 poster 3122 Updated BSI-201 SABCS 2009 Copyright © 2010, Research To Practice, All rights reserved.

Conclusions Single agent synthetic lethality concept shown for olaparib in BRCA1 and BRCA2 mutation carriers with advanced breast and advanced ovarian cancer Randomised phase II data for BSI-201 very promising for PARPi combined with gemcitabine/ carboplatin in sporadic TNBC Phase III RCT of BSI-201 gemcitabine/carboplatin completed and results awaited Consideration of investigation of novel PARPi/ chemotherapy combinations in advanced disease and in early breast cancer trials in TNBC and BRCA1 and BRCA2 carriers

Copyright © 2010, Research To Practice, All rights reserved. Acknowledgements Our patients and their families ICEBERG Investigators BRCA carrier advocacy community – FORCE – Susan G Komen ICR Breakthrough Centre – Alan Ashworth, Chris Lord, Hannah Farmer, Nuala McCabe – Nick Turner, Jorge Reis-Filho KCL Breakthrough Unit Cancer Research UK KuDOS/AstraZeneca – Stephen Jackson, Niall Graham Graeme Smith, Jim Carmichael